Muttenz – Clariant, a world leader in specialty chemicals, announced today the expansion of the capacity of its ethylene oxide (EO) unit in Gendorf, Germany. The investment positions Clariant to continue its successful development of innovative EO-based specialties to support a wide range of industries, such as personal and home care, crop solutions, and industrial applications. No further details of the investment will be disclosed.
“As a globally leading company for specialty chemicals, Clariant continues to invest also in our production network in Europe. I am confident that this sizeable expansion will support our strategic goal of intensifying profitable growth in both developed and emerging markets”, said Christian Kohlpaintner, member of Clariant's Executive Committee.
The expansion of Clariant’s state-of-the-art facilities at Gendorf will enable higher production yields, greater process reliability and enhanced product quality. An increase of High Purified Ethylene Oxide (HPEO) is expected to be available from 2020. João Tavares Correia, Head of the RBL EMEA region, Business Unit Industrial & Consumer Specialties at Clariant, comments: “We are pleased to announce this strategic investment for Gendorf committing to the long-term growth of our customers across our different markets. With this capacity increase of High Purified Ethylene Oxide (HPEO), Clariant will continue to expand its market driven innovative portfolio of EO-based specialties.”
DSM significantly reduces CO2 emissions at vitamin production facility in Sisseln, Switzerland
DSM announced that it reduces CO2 emissions at its vitamin production facility in Sisseln, Switzerland, by 50,000 tons/year.
Nouryon starts work on chloromethanes expansion in Germany
Nouryon will start construction in May on a project to further increase capacity for chloromethanes at its site in Frankfurt, Germany. The expansion is expected to be completed in 2020.
Ercros expands its moulding compounds production capacity
The Ercros factory in Cerdanyola has expanded the production capacity of moulding compounds by 3,000 t/year, which represents an increase of 14% to reach 25,000 t/year.
Merck Invests in Expansion of Manufacturing Capacity for Biotech Medicines
€150 million investment over the 2019-2023 period in manufacturing site at Aubonne, Switzerland. Expansion supports growth of current and future portfolio of Merck’s biotech medicines for patients ...